ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

6 links2 made here, not in the record11 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06624644A Trial of LNS8801 With orWithout Pembrolizumab inPatients With RefractoryMelanomaLinnaeus Therapeutics, Inc.Phase 2/Phase 3 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSMelanomaThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSINT018017Entry “LNS8801”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT009932Entry “Immunotherapy (Pembrolizumab)”…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · TestedNov 18 · Rule based · ComparatorComparatorNivolumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · ComparatorComparatorIpilimumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

INT018017

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “LNS8801”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2INT018017Claude Opus 5.5TestedCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2INT009932Claude Opus 5.5ComparatorCurrent
Nov 2Nivolumabmade hereClaude Opus 5.5ComparatorCurrent
Nov 2Ipilimumabmade hereClaude Opus 5.5ComparatorCurrent
Nov 14MelanomaRule based · condition-kind ruleFinest filed termCurrent
Nov 18INT018017Rule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18INT009932Rule based · role ruleTestedOverridden
Nov 18INT009932Rule based · role ruleComparatorAgrees
As of nowMelanomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.